Vident Advisory LLC Sells 25,324 Shares of DexCom, Inc. (NASDAQ:DXCM)

Vident Advisory LLC decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 82.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,217 shares of the medical device company's stock after selling 25,324 shares during the quarter. Vident Advisory LLC's holdings in DexCom were worth $406,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Private Trust Co. NA boosted its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of DexCom during the 4th quarter worth about $33,000. TD Private Client Wealth LLC boosted its stake in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Trading Up 1.3%

DXCM traded up $1.10 during mid-day trading on Friday, reaching $85.96. The stock had a trading volume of 4,257,051 shares, compared to its average volume of 4,375,931. The firm's fifty day simple moving average is $74.42 and its two-hundred day simple moving average is $78.57. The stock has a market capitalization of $33.71 billion, a P/E ratio of 60.11, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $127.61. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 earnings per share. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DXCM. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Citigroup reaffirmed a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Canaccord Genuity Group lifted their target price on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Finally, Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $98.32.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 83,110 shares of company stock valued at $6,103,505 in the last 90 days. 0.32% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.